SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?


To: Arthur Radley who wrote (104)1/27/1999 5:49:00 PM
From: Biomaven  Read Replies (1) | Respond to of 3158
 
TexasDude,

My instinct is that LGND isn't a prime candidate right now. (If that isn't enough to produce the "X acquires LGND" headline in the next few days, I don't know what is <G>).

First, LGND has a complex web of partners. This doesn't make a takeover impossible, but it certainly makes it more awkward.

Second, LGND is complicated to understand and big enough so nobody is going to casually buy them without a very thorough understanding of what they have to offer.

Finally, LGND would get a much better price if they wait until they are profitable, which (if you can believe them, which I'm not sure I do) is just around the next fiscal year corner.

LGND has always seemed to have more IP than resources, so a takeover would ultimately be a win-win. I just don't think the time and circumstances are right yet.

Peter



To: Arthur Radley who wrote (104)1/28/1999 4:40:00 AM
From: Henry Niman  Respond to of 3158
 
Volume is probably related to anticipated FDA approvals, and spike at the end of yesterday may be due to TokyoMex picking LGND (based on FDA approval):
tokyojoe.com